Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1233 EUR
−20.34 M EUR
1.80 M EUR
133.56 M
About VALERIO THERAPEUTICS EUR0.25
Sector
CEO
Julien Miara
Headquarters
Paris
Website
Founded
1997
ISIN
FR0010095596
FIGI
BBG00JHW08Z3
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of oncology drugs targeting tumor intracellular processes. The firm produces and develops orphan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA. The company was founded by Jean Theron, Gilles Avenard, and Dominique Costantini on March 5, 1997 and is headquartered in Paris, France.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 0NWK is 0.0780 EUR — it has decreased by −9.30% in the past 24 hours. Watch VALERIO THERAPEUTICS EUR0.25 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange VALERIO THERAPEUTICS EUR0.25 stocks are traded under the ticker 0NWK.
0NWK stock has fallen by −9.30% compared to the previous week, the month change is a −9.30% fall, over the last year VALERIO THERAPEUTICS EUR0.25 has showed a −58.62% decrease.
0NWK reached its all-time high on Jan 10, 2018 with the price of 2.3143 EUR, and its all-time low was 0.0780 EUR and was reached on Nov 27, 2024. View more price dynamics on 0NWK chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
0NWK stock is 10.26% volatile and has beta coefficient of −0.04. Track VALERIO THERAPEUTICS EUR0.25 stock price on the chart and check out the list of the most volatile stocks — is VALERIO THERAPEUTICS EUR0.25 there?
Today VALERIO THERAPEUTICS EUR0.25 has the market capitalization of 11.24 M, it has decreased by −9.00% over the last week.
Yes, you can track VALERIO THERAPEUTICS EUR0.25 financials in yearly and quarterly reports right on TradingView.
VALERIO THERAPEUTICS EUR0.25 is going to release the next earnings report on Mar 27, 2025. Keep track of upcoming events with our Earnings Calendar.
0NWK net income for the last half-year is −10.96 M EUR, while the previous report showed −8.70 M EUR of net income which accounts for −25.95% change. Track more VALERIO THERAPEUTICS EUR0.25 financial stats to get the full picture.
No, 0NWK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VALERIO THERAPEUTICS EUR0.25 EBITDA is −18.55 M EUR, and current EBITDA margin is −1.16 K%. See more stats in VALERIO THERAPEUTICS EUR0.25 financial statements.
Like other stocks, 0NWK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VALERIO THERAPEUTICS EUR0.25 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VALERIO THERAPEUTICS EUR0.25 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VALERIO THERAPEUTICS EUR0.25 stock shows the sell signal. See more of VALERIO THERAPEUTICS EUR0.25 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.